Reviva Pharmaceuticals to Showcase New Findings on Brilaroxazine
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a forward-thinking biopharmaceutical company, is making waves in the medical industry with its recent developments. This company primarily focuses on addressing unmet medical needs within central nervous system (CNS), inflammatory, and cardiometabolic diseases. Exciting news arrives as Reviva prepares to present new topline data concerning the long-term open label extension of the Phase 3 RECOVER study on brilaroxazine, a novel treatment for schizophrenia.
Details of the Oral Presentation at SIRS Congress
As part of the upcoming Congress of the Schizophrenia International Research Society (SIRS), Reviva will conduct an oral presentation featuring these important findings. This event is set to occur from March 29 to April 2, drawing attention from scholars and professionals in the mental health field.
Presentation Title and Details
The presentation is titled "Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants." An exploration into the efficacy and safety of the treatment over an extended period promises to shed light on its potential benefits for patients.
The Session Topic
Taking place within the Pharmaceutical Pipeline session, the presentation aims to engage stakeholders in the pharmaceutical industry, discussing cutting-edge advancements that can transform mental health treatments. Dr. Laxminarayan Bhat, the founder and CEO of Reviva, will lead this insightful session, highlighting the company's dedication to tackling challenging health issues.
About Brilaroxazine
Brilaroxazine is a pioneering drug candidate designed to provide effective treatment options for individuals suffering from schizophrenia. As one of Reviva’s primary therapeutic candidates, brilaroxazine showcases a commitment to discovering novel solutions for debilitating conditions. This drug, alongside another candidate, RP1208, uniquely developed in-house, signifies Reviva's dedication to innovative treatments.
Reviva's Mission and Vision
Reviva's mission extends beyond just developing and commercializing new therapeutics; it fully dedicates itself to alleviating burdens faced by patients and their families. The company recognizes the daunting challenges presented by CNS and other disorders, which emphasizes the importance of this ongoing research. Reviva emphasizes its commitment to bringing groundbreaking and effective solutions to market while ensuring safety and efficacy are paramount in its drug development processes.
Corporate and Investor Relations
For investors and stakeholders, clear communication remains crucial. Reviva encourages individuals seeking information to connect directly with its corporate representatives. Laxminarayan Bhat, PhD, can be contacted for inquiries or further information regarding the company's ongoing initiatives.
Frequently Asked Questions
What is Reviva Pharmaceuticals focusing on?
Reviva Pharmaceuticals is dedicated to developing therapies for CNS, inflammatory, and cardiometabolic diseases, addressing significant medical needs.
When will the oral presentation take place?
The presentation is scheduled for March 30, at the SIRS Congress, from 10:30 AM to 12:00 PM ET CST.
Who will present the findings from the RECOVER study?
Dr. Laxminarayan Bhat, founder and CEO of Reviva Pharmaceuticals, will be delivering the presentation.
What is the significance of brilaroxazine?
Brilaroxazine represents a novel treatment approach for schizophrenia, contributing to the growing array of solutions for managing this condition.
How can I reach Reviva Pharmaceuticals for inquiries?
For more information, you can contact Laxminarayan Bhat at Reviva Pharmaceuticals directly.
